Company intelligence / Profile preview
ZymIQ Technology
Lund, Skåne, Swedenzymiq.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ZymIQ's enzyme technology demonstrates rapid and effective elimination of mycobacteria in preclinical in vivo models, including activity against dormant bacteria and synergy with antibiotics, indicating potential for faster and more efficient treatment of hard-to-treat bacterial infections compared to current standard therapies.[5]
- Therapeutic areas
- Infectious DiseasesDermatologyOther
- Modalities
- Enzyme-based therapyPhage-based therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
fjör (cosmetic applications)
Beyond the preview
Go deeper on ZymIQ Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZymIQ Technology.